The Chinese tech giant on Friday announced that it entered into definitive agreements on May 9 for non-redeemable Series A preferred share financing for JD Health. The shares on offer represent over 14.5 per cent of equity interest in JD Health on a fully diluted basis.
Create an account to continue reading this premium story for freeRegister
Already a Subscriber? Log in